# A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors

Source: https://onco.cc/trials/nct06237881/  
OnCo record `nct06237881` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of KSQ-001EX run by M.D. Anderson Cancer Center, active, not recruiting.

## Summary

A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06237881 by M.D. Anderson Cancer Center, with 15 participants planned, started 2024-01-31, primary completion expected 2027-01-01. Conditions recorded: Advanced Solid Tumor, Melanoma, Lung Neoplasms, Head and Neck Neoplasms. Interventions recorded: KSQ-001EX, Interleukin-2, Cyclophosphamide, Fludarabine.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-11-04
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06237881
- Phase: 1/2
- Setting: A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors
- Sponsor: M.D. Anderson Cancer Center
- Enrolled: 15

## Sources

- ClinicalTrials.gov NCT06237881: https://clinicaltrials.gov/study/NCT06237881

## Connected records

- cancers: [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [Melanoma](https://onco.cc/cancers/melanoma/)
- drugs: [KSQ-001EX](https://onco.cc/drugs/ksq-001ex/)
- companies: [KSQ Therapeutics](https://onco.cc/companies/ksq-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct06237881.json